U.S. FDA Wants More Information On AstraZeneca PLC Lung Drug

LONDON, Aug 30 (Reuters) - AstraZeneca’s MedImmune biologics unit has been asked by U.S regulators for more information on its infant lung drug motavizumab after drug regulatory advisors recommended against approving it in June.

MORE ON THIS TOPIC